Results of the star*D study: Implications for clinicians and drug developers

Journal of Psychiatric Practice

Volumn 15, Issue 1, 2009, Pages 45-49

  Preskorn, Sheldon H ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; DESVENLAFAXINE; DOPAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORADRENALIN; NORTRIPTYLINE; PAROXETINE; PENICILLIN G; SELEGILINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; HEALTH CARE PERSONNEL; HUMAN; INFECTION; MEDICAL DECISION MAKING; MONOTHERAPY; PRESCRIPTION; PSYCHOPHARMACOLOGY; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE; DRUG INDUSTRY; DRUG TOLERANCE; RANDOMIZED CONTROLLED TRIAL;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG INDUSTRY; DRUG TOLERANCE; HUMANS; MONOAMINE OXIDASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION;

EID: 67650135637     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000344918.51404.1e     Document Type: Article

References (20)

1. Understanding the basics of antidepressant pharmacology. Series of columns published between 1998 and 2000 in the Journal of Practical Psychiatry and Behavioral Health and the Journal of Psychiatric Practice. Available at www.preskorn.com/column2.html.
2. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry 2006;163:28-40.
3. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:1243-52.
4. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354:1231-42.
5. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: A STAR*D report. Am J Psychiatry 2006;163:1161-72.
6. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: A STAR*D report. Am J Psychiatry 2006;163:1519-30.
7. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: A STAR*D report. Am J Psychiatry 2006;163:1531-41.
8. Warden D, Rush AJ, Trivedi MH, et al. STAR*D Project results: A comprehensive review of findings. Curr Psychiatry Rep 2007;9:449-59.
9. Preskorn SH. The appearance of knowledge. Journal ofPractical Psychiatry and Behavioral Health 1997;3:233-8.
10. Nierenberg AA, White K. What next? A review of pharma-cologic strategies for treatment resistant depression. Psychopharmacol Bull 1990;26:429-60.
11. Rush AJ, Kupfer DJ. Strategies and tactics in the treatment of depression. In: Gabbard GO, ed. Treatments of psychiatric disorders, second edition. Washington, DC: American Psychiatric Press; 2001: 1427-8.
12. Thase ME, Rush AJ. When at first you don't succeed: Sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997;58(suppl 13):23-9.
13. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
14. IMS National Prescription Audit, Dispensed New Rx's, Month September 2008.
15. Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: A randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 2006;63: 1121-9.
16. Garlapati V, Boyer WF, Feighner JP. Promising new directions in antidepressant development. In: Preskorn, SH, Feighner JP, Stanga CY, et al. Antidepressants: Past, present and future. New York: Springer-Verlag Berlin Heidelberg; 2004:565-82.
17. Gilligan PJ, Li YW. Corticotropin-releasing factor antagonists: Recent advances and exciting prospects for the treatment of human diseases. Curr Opin Drug Discov Devel 2004;7:487-97.
18. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351-4.
19. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63:856-64.
20. Preskorn SH, Baker B, Kolluri S, et al. Antidepressant effects of the NR2B NMDA antagonist: An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspar-tate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psycho-pharmacology 2008;28:631-7.